

# Nuclear Factor Erythroid 2–Related Factor 2 Deficiency Results in Amplification of the Liver Fat-Lowering Effect of Estrogen<sup>§</sup>

Wenjuan Rui, Yuhong Zou, Joonyong Lee, Shashank Manohar Nambiar, Jingmei Lin, Linjie Zhang, Yan Yang, and Guoli Dai

Department of Pharmacology and Immunology, Anhui Medical University, Hefei, China (W.R., L.Z., Y.Y.); Department of Biology, School of Science, Center for Developmental and Regenerative Biology, Indiana University–Purdue University Indianapolis, Indianapolis, Indiana (W.R., Y.Z., S.M.N., G.D.); and Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana (J.L.)

Received January 19, 2016; accepted May 5, 2016

## ABSTRACT

Transcription factor nuclear factor erythroid 2–related factor 2 (Nrf2) regulates multiple biologic processes, including hepatic lipid metabolism. Estrogen exerts actions affecting energy homeostasis, including a liver fat-lowering effect. Increasing evidence indicates the crosstalk between these two molecules. The aim of this study was to evaluate whether Nrf2 modulates estrogen signaling in hepatic lipid metabolism. Nonalcoholic fatty liver disease (NAFLD) was induced in wild-type and *Nrf2*-null mice fed a high-fat diet and the liver fat-lowering effect of exogenous estrogen was subsequently assessed. We found that exogenous estrogen eliminated

49% and 90% of hepatic triglycerides in wild-type and *Nrf2*-null mice with NAFLD, respectively. This observation demonstrates that Nrf2 signaling is antagonistic to estrogen signaling in hepatic fat metabolism; thus, *Nrf2* absence results in striking amplification of the liver fat-lowering effect of estrogen. In addition, we found the association of trefoil factor 3 and fatty acid binding protein 5 with the liver fat-lowering effect of estrogen. In summary, we identified Nrf2 as a novel and potent inhibitor of estrogen signaling in hepatic lipid metabolism. Our finding may provide a potential strategy to treat NAFLD by dually targeting Nrf2 and estrogen signaling.

## Introduction

Estrogen, via its nuclear receptors estrogen receptor (ER)  $\alpha$  and ER $\beta$  and membrane-bound ER, regulates energy homeostasis in addition to its well established essential roles in reproduction (Barros and Gustafsson, 2011; Xu et al., 2011). Many studies have demonstrated that, irrespective of gender, estrogen (predominantly relying on ER $\alpha$ ) exerts body weight-lowering, adiposity-lowering, and antidiabetic effects through systematic and tissue-specific mechanisms in both rodents and humans. The pivotal roles of estrogen signaling in the metabolic network were thoroughly reviewed by several groups recently (Roepke, 2009; Barros and Gustafsson, 2011; Mauvais-Jarvis et al., 2013; Frank et al., 2014; Kim et al., 2014; Palmer and Clegg, 2015). The liver is one of the key organs coordinately controlling energy homeostasis, including lipid metabolism. Hepatic estrogen signaling is critical for maintaining lipid homeostasis in the liver (Han et al., 2014; Shen and Shi, 2015). Nonalcoholic fatty liver disease (NAFLD), primarily manifested by excessive fat accumulation in hepatocytes, has become the most common chronic liver disease worldwide (Demir et al., 2015). A number of studies consistently

showed that estrogen displays a fat-lowering effect by presumably inhibiting lipogenesis and promoting lipolysis in the liver in a variety of animal models, including genetically manipulated mice, ovariectomized rodents, spontaneous obese mice, and rodents with diet-induced metabolic syndrome (Jones et al., 2000; Hewitt et al., 2004; Gao et al., 2006; Bryzgalova et al., 2008; Lundholm et al., 2008; Pedram et al., 2013; Zhang et al., 2013a; Han et al., 2014). However, the mechanisms behind those observations, especially how the fat-lowering action of estrogen is modulated in the liver, remain elusive.

As a leucine zipper motif-containing transcription factor, nuclear factor erythroid 2–related factor 2 (Nrf2) essentially mediates the cellular response against redox stress. Its target genes include those encoding cytoprotective proteins, such as detoxifying enzymes, glutathione synthesis enzymes, and antioxidant proteins, thereby positively or negatively contributing to carcinogenesis, drug resistance, and many degenerative diseases (Dodson et al., 2015; Huang et al., 2015; Suzuki and Yamamoto, 2015; Tebay et al., 2015). Depending on a disease condition, activation or suppression of Nrf2 is believed to be a promising therapeutic strategy. In addition, Nrf2 regulates carbohydrate and lipid metabolism, participating in the development and progression of NAFLD despite contradictory findings in the literature (Chambel et al., 2015; Tebay et al., 2015).

Several lines of evidence suggest a unidirectional positive or negative effect of estrogen signaling on Nrf2 activity in a cell

This research was supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grant 7R01DK07596].

W.R. and Y.Z. contributed equally to this work.

[dx.doi.org/10.1124/jpet.115.231316](http://dx.doi.org/10.1124/jpet.115.231316)

<sup>§</sup> This article has supplemental material available at [jpet.aspetjournals.org](http://jpet.aspetjournals.org).

**ABBREVIATIONS:** DIO, diet-induced obesity; E2, estradiol-17 $\beta$ ; ER, estrogen receptor; HFD, high-fat diet; I/R, liver ischemia and reperfusion; LXR, liver X receptor; NAFLD, nonalcoholic fatty liver disease; NQO-1, NAD(P)H:quinone oxidoreductase 1; PCR, polymerase chain reaction.

type- or tissue-dependent manner. Estrogen stimulates Nrf2 activation in epithelial cells of the mammary gland, cerebral nerve tissue, primary myocardial cells, umbilical vein endothelial cells, ovarian epithelial carcinoma, and breast cancer cells (Liao et al., 2012; Yu et al., 2012; Zhang et al., 2013b; Gorrini et al., 2014; Meng et al., 2014; Wu et al., 2014). In contrast, estrogen potently inhibits the activities of Nrf2 target proteins (glutathione-S-transferase and quinone reductase), specifically in the uterus, possibly via its ligand-dependent interaction with Nrf2 (Ansell et al., 2004, 2005). The liver highly expresses both ER $\alpha$  and Nrf2, both of which are involved in hepatic lipid metabolism (Chan et al., 1996; Kuiper et al., 1997). We were interested in whether there is a connection between Nrf2 and estrogen signaling in NAFLD.

In our studies, NAFLD was induced in wild-type and Nrf2-null mice fed a high-fat diet (HFD), which was followed by an estradiol-17 $\beta$  (E2) treatment regimen. We found that the lack of Nrf2 results in a marked increase in hepatic ER $\alpha$  basal expression and striking amplification of the liver fat-lowering effect of E2. These findings demonstrate Nrf2 as a new and potent negative modulator of estrogen signaling in hepatic lipid metabolism.

## Materials and Methods

**Animal Care and Use.** Nrf2<sup>+/+</sup> and Nrf2<sup>-/-</sup> male mice of a C57BL/6J129SV mixed background were used for the study (Chan et al., 1996). Standard rodent chow and drinking water were provided ad libitum throughout the experiment. To induce NAFLD, mice were given a HFD (TD.88137; Harlan Laboratories, Madison, WI) for 16 weeks. Afterward, mice received vehicle (sesame oil), E2 (25  $\mu$ g/mouse; Sigma-Aldrich, St. Louis, MO) (Bourassa et al., 1996), progesterone (1 mg/mouse; Sigma-Aldrich) (Walter et al., 2005), or a combination of these two steroid hormones (25  $\mu$ g E2 and 1 mg progesterone/mouse) subcutaneously once daily for 3 weeks, while they were continuously fed the HFD. Animals were euthanized 4 hours after the last dosing. All of the animal experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Protocols for the care and use of animals were approved by the Indiana University–Purdue University Indianapolis Animal Care and Use Committee.

**Histology and Immunohistochemistry.** Liver specimens embedded in paraffin were sliced at 5- $\mu$ m thickness and stained with hematoxylin and eosin to examine liver histology. Liver sections were subjected to immunostaining with a fatty acid binding protein 5 (FABP5) antibody (GTX12109; GeneTex, Irvine, CA) or a trefoil factor 3 (TFF3) primary antibody (TFF331-A; Alpha Diagnostic, San Antonio, TX) according to the manufacturer's instructions. Optimal cryo embedding medium-embedded liver specimens were cut into 10- $\mu$ m thickness and stained with Oil Red O to visualize intracellular lipid droplets.

**Measurement of Liver Lipid Content.** Hepatic triglycerides, total cholesterol, and free fatty acids were quantified using commercially available kits (ab65336, ab65359, and ab65341; Abcam, Cambridge, MA) according to the manufacturer's instructions.

**Mouse Fatty Liver RT<sup>2</sup> Profiler Polymerase Chain Reaction Array.** Total RNA was extracted from the livers using TRIzol reagent (Invitrogen, Carlsbad, CA). cDNAs were synthesized from 500 ng total RNA for each sample using the RT<sup>2</sup> First-Strand Kit (330401; Qiagen, Valencia, CA). The Mouse Fatty Liver RT<sup>2</sup> Profiler PCR Array, which profiles the expression of 84 key genes involved in the mechanisms of NAFLD and hepatic insulin resistance, and RT<sup>2</sup> SYBR Green ROX qPCR Master Mix were purchased from Qiagen (PAMM-157Z, 330520). The amplification reactions were carried out with the ABI Prism 7900 sequence detection system (Applied Biosystems, Foster City, CA). Fold changes in gene expression between different groups

were calculated using the comparative threshold cycle method in the PCR Array Data Analysis template from Qiagen.

**Quantitative Real-Time Polymerase Chain Reaction.** Total RNA was isolated from each frozen liver using TRIzol reagent according to the manufacturer's protocol (Invitrogen). cDNAs were synthesized from 1  $\mu$ g total RNA of each sample using a Verso cDNA Kit (Thermo Scientific, Rockford, IL), diluted four times with water, and subjected to quantitative real-time polymerase chain reaction (PCR). TaqMan Universal PCR Master Mix and the primers and TaqMan MGB probes of mouse Nrf2 (Mm00477786\_m1), NAD(P)H: quinone oxidoreductase (NQO)-1 (NQO-1) (Mm01253561\_m1), ER $\alpha$  (Mm00433149\_m1), ER $\beta$  (Mm00599821\_m1), TFF3 (Mm00495590\_m1), FABP5 (Mm00783731\_s1), and albumin (Mm00802090\_m1) were purchased from Applied Biosystems. The amplification reactions were carried out with the ABI Prism 7900 sequence detection system (Applied Biosystems) with initial hold steps (50°C for 2 minutes followed by 95°C for 10 minutes) and 40 cycles of a two-step PCR (92°C for 15 seconds and 60°C for 1 minute). The comparative threshold cycle method was used for the relative quantification of the amount of mRNA in each sample normalized to the albumin transcript levels.

**Western Blot Analysis.** Liver homogenates (10  $\mu$ g) were separated by PAGE under reducing conditions. Proteins from the gels were electrophoretically transferred to polyvinylidene difluoride membranes. Antibodies against NQO-1 (ab80588; Abcam), ER $\alpha$  (SC-514910; Santa Cruz Biotechnology, Santa Cruz, CA), FABP5 (GTX12109; GeneTex), and glyceraldehyde-3-phosphate dehydrogenase (SC-130656; Santa Cruz Biotechnology) were used as probes. Immune complexes were detected using the enhanced chemiluminescence system (Pierce, Rockford, IL).


**Statistical Analysis.** Data are shown as means  $\pm$  S.D. Statistical analysis was performed using a one-way analysis of variance or *t* test. Significant differences were defined when *P* < 0.05.

## Results

### Nrf2 Absence Results in a Strikingly Enhanced Liver Fat-Lowering Effect of Estrogen in Mice with NAFLD.

To determine whether Nrf2 modulates estrogen signaling in hepatic fat metabolism, we fed adult male wild-type and Nrf2-null mice a HFD for 4 months to induce NAFLD. Afterward, we treated mice with both genotypes with vehicle, E2, progesterone, or a combination of E2 and progesterone once per day for 3 weeks. During the steroid hormone treatment period, mice were continuously fed the HFD. Progesterone often exerts opposite effects to estrogen in many tissues (Diep et al., 2015). Hence, progesterone served as a potential negative control, whereas the combination of the two steroid hormones was used as a potential antagonistic control.

We first examined the liver size and hepatic histology. We found that Nrf2 absence caused a slight but significant reduction in liver-to-body weight ratio in mice fed a normal chow, as reported (Huang et al., 2010; Zou et al., 2014) (Fig. 1). The HFD induced liver enlargement and massive hepatic fat accumulation in both wild-type and Nrf2-null mice in the vehicle control group (Figs. 1 and 2). Compared with the vehicle control, exogenous estrogen resulted in decreases in liver size and hepatic fat deposition in both genotype groups of mice, exerting a liver fat-lowering effect, as demonstrated by others (Gao et al., 2006; Bryzgalova et al., 2008; Han et al., 2014) (Figs. 1 and 2). Notably, histologic assessment revealed that this effect was evidently enhanced when Nrf2 was lacking, which was manifested by a further reduction in liver fat accumulation in Nrf2-null mice (Fig. 2). This finding indicates that Nrf2 counteracts with estrogen signaling in hepatic lipid metabolism. Relative to the vehicle control,



**Fig. 1.** Liver-to-body weight ratios. Adult male wild-type (*Nrf2*<sup>+/+</sup>) and *Nrf2*-null (*Nrf2*<sup>-/-</sup>) mice were fed a HFD for 16 weeks. Afterward, vehicle (sesame oil), E2 (625  $\mu$ g/kg), progesterone (P, 25 mg/kg), or a combination of these two steroids (625  $\mu$ g/kg E2 and 25 mg/kg progesterone) was injected subcutaneously once daily for 3 weeks. At 4 hours after the last dosing, mice were weighed and then euthanized for sample collection. *Nrf2*<sup>+/+</sup> and *Nrf2*<sup>-/-</sup> mice fed a normal chow served as homeostasis controls. The liver-to-body weight ratios were calculated and are shown. \**P* < 0.05, compared with normal chow-fed *Nrf2*<sup>+/+</sup> mice; #*P* < 0.05, compared with normal chow-fed *Nrf2*<sup>-/-</sup> mice; †*P* < 0.05, compared as indicated. *n* = 5.


irrespective of genotype, exogenous progesterone did not overtly affect liver size and fat deposition (Figs. 1 and 2). However, regardless of genotype, the liver fat-lowering effect of estrogen was largely prevented in the estrogen and progesterone combination treatment group (Fig. 2), indicating that progesterone antagonizes the action of estrogen in eliminating hepatic fat content. Together, our findings demonstrate that *Nrf2* negatively modulates estrogen signaling in NAFLD.

To further demonstrate the above findings, we performed Oil Red O staining on liver sections to visualize fat deposition. As a result, compared with the vehicle control, estrogen administration reduced liver fat staining in wild-type mice and, strikingly, almost diminished that in *Nrf2*-null mice (Fig. 3A). We subsequently quantified hepatic lipid contents. Relative to normal chow, the HFD induced excessive accumulation of triglycerides, total cholesterol, and free fatty acids in the liver, which were equivalent quantitatively between wild-type and *Nrf2*-null mice (Fig. 3B). In wild-type mice, relative to the vehicle control, exogenous estrogen decreased hepatic triglycerides by 49% and free fatty acids by 25% but did not significantly affect total cholesterol (Fig. 3B). When *Nrf2* was absent, exogenous estrogen reduced hepatic triglycerides by 90%, free fatty acids by 54%, and total cholesterol by 37% (Fig. 3B). The data together demonstrate that the liver fat-lowering effect of estrogen is drastically heightened because of the lack of *Nrf2*, indicating that *Nrf2* is antagonistic to estrogen signaling in hepatic fat metabolism.

***Nrf2* Absence Causes a Marked Increase in Exogenous Estrogen-Induced Hepatic Estrogen Signaling in Mice with NAFLD.** We evaluated hepatic *Nrf2* signaling by assessing the mRNA expression of *Nrf2* and its typical target

gene *NQO-1* in the liver (Chan et al., 2001) (Fig. 4A). As expected, in normal chow-fed mice, *Nrf2* deficiency led to a reduction in the basal level of hepatic *NQO-1* mRNA. HFD feeding highly activated *Nrf2* in wild-type mice, relative to normal chow feeding, which was manifested by 8-fold and 6-fold upregulation in *Nrf2* and *NQO-1* gene expression, respectively. As a result of *Nrf2* genetic deletion, *NQO-1* mRNA did not respond to the HFD. The data demonstrate that *NQO-1* expression is solely controlled by *Nrf2* in this disease condition, reliably reflecting *Nrf2* activity. In wild-type mice with NAFLD, compared with the vehicle control, estrogen administration did not significantly alter *Nrf2*, while marginally increased *NQO-1* transcript level. The data indicate that exogenous estrogen slightly increased HFD-induced activation of hepatic *Nrf2*. In addition, excessive estrogen did not significantly influence *Nrf2*-dependent regulation of hepatic *NQO-1* gene in this disease. This observation indicates that estrogen signaling does not independently control *NQO-1* mRNA expression. Furthermore, we showed that *NQO-1* mRNA expression was consistent with its protein expression in the liver in various conditions (Fig. 4B). Taken together, we demonstrate that hepatic *Nrf2* is highly activated in NAFLD and exogenous estrogen can somewhat further increase hepatic *Nrf2* activity in this condition.

We next assessed hepatic ER signaling by evaluating the expression of *ER $\alpha$* , *ER $\beta$* , and *TFF3* genes (Fig. 4A) and *ER $\alpha$*  protein (Fig. 4B) in the liver. *TFF3* is an estrogen-responsive gene; thus, its mRNA expression was used to estimate ER activity (May and Westley, 1997; Gruvberger et al., 2001). In normal chow-fed mice, *Nrf2* deficiency caused a 6.5-fold increase in hepatic *ER $\alpha$*  mRNA expression. Both wild-type and *Nrf2*-null mice fed the normal chow displayed variable expression of hepatic *ER $\alpha$*  protein. Notably, in normal chow-fed mice, *Nrf2* absence resulted in a 4.5-fold elevation in the hepatic *TFF3* mRNA level, indicating higher *ER $\alpha$*  activity. This finding suggests that *Nrf2* may be a suppressor of *ER $\alpha$*  signaling in the homeostasis condition. Compared with normal chow feeding, HFD feeding increased and reduced hepatic *ER $\alpha$*  mRNA expression in wild-type and *Nrf2*-null mice, respectively, resulting in equivalent *ER $\alpha$*  mRNA levels between the two genotypes. Relative to normal chow feeding, HFD feeding induced overt increases in hepatic *ER $\alpha$*  protein expression in both wild-type and *Nrf2*-null mice. Taken together, these data indicate that mRNA and protein of hepatic *ER $\alpha$*  differentially respond to the disease state in their expression. Compared with normal chow feeding, HFD feeding did not affect *Nrf2*-dependent basal *TFF3* transcript expression, showing that HFD does not alter *Nrf2*-dependent basal activity of hepatic *ER $\alpha$* . Remarkably, relative to the vehicle control in wild-type mice, E2 administration elevated hepatic *TFF3* mRNA expression by 122-fold in the presence of *Nrf2* and by 480-fold in the absence of *Nrf2*. Immunohistochemical analysis showed that hepatic *TFF3* protein was mainly induced in hepatocytes (Fig. 4C). The data demonstrate that the lack of *Nrf2* leads to an astonishing enhancement of exogenous estrogen-induced hepatic ER signaling in NAFLD. Collectively, these findings demonstrate that *Nrf2* antagonizes hepatic estrogen signaling and *Nrf2* deficiency thereby results in amplification of the clearing effect of exogenous estrogen on liver fat. In addition, the hepatic *TFF3* level positively correlates with the liver fat-lowering effect of estrogen. *ER $\beta$*  mRNA was barely detected across the



**Fig. 2.** Histologic assessments of liver sections. Livers were collected from the experiment described in Fig. 1. Formalin-fixed and paraffin-embedded liver sections were stained with hematoxylin and eosin and were visualized at low magnification (A) and high magnification (B). Original magnification,  $\times 100$  in A;  $\times 400$  in B.

samples (data not shown), indicating that ER $\alpha$  dominantly mediates the action of estrogen in the liver.


**FABP5 Is Induced in an Nrf2- and Exogenous Estrogen-Dependent Manner in Mice with NAFLD.** To gain further insight into the above findings, we analyzed hepatic expression of 84 key genes involved in the mechanisms of NAFLD and hepatic insulin resistance by a Mouse Fatty Liver RT<sup>2</sup> Profiler PCR Array in both genotype groups of mice with NAFLD (Supplemental Table 1). Surprisingly, we found that only FABP5 exhibited both Nrf2- and exogenous estrogen-dependent changes. The data were validated by quantitative real-time PCR (Fig. 5A). In normal chow-fed mice, *Nrf2* deficiency resulted in a 6.5-fold increase in hepatic FABP5 mRNA expression. The data indicate that Nrf2 suppresses FABP5 basal expression in the liver in the homeostasis condition. Compared with normal chow feeding, HFD feeding suppressed hepatic *FABP5* gene expression in both genotype groups of mice. Compared with vehicle controls, E2 treatment led to increases in hepatic FABP5 mRNA irrespective of genotype in mice with NAFLD. Notably, the magnitude of exogenous estrogen-induced elevation of hepatic FABP5 transcription in Nrf2-null mice was 2.4-fold higher than that in wild-type mice. Western blotting and immunohistochemical analyses

of hepatic FABP5 protein further demonstrated the finding at the protein level and revealed its expression in hepatocytes (Figs. 4B and 5B). The data indicate that 1) FABP5 is a novel estrogen-responsive gene in the liver, 2) Nrf2 limits exogenous estrogen-induced elevation of hepatic FABP5, and 3) FABP5 positively correlates with the liver fat-lowering effect of estrogen.

## Discussion

These studies identified Nrf2 as a potent suppressor of estrogen signaling in the liver. We provided two pieces of evidence to support our notion. First, in a homeostasis condition, *Nrf2* deficiency resulted in enhanced hepatic estrogen signaling, manifested by elevated expression of its target gene *TFF3*. Second, in NAFLD, the lack of *Nrf2* led to drastically increased activation of hepatic estrogen signaling by E2, reflected by a markedly elevated *TFF3* induction and highly enhanced liver fat-lowering effect of E2. The exact mechanism underlying the crosstalk between Nrf2 and estrogen signaling must be further investigated. It has been reported that Nrf2 directly interacts with ER $\alpha$  at the protein







**Fig. 3.** Liver fat assessments. Livers were harvested from the experiment indicated in Fig. 1. (A) Oil Red O staining of liver fat. Frozen liver sections were stained with Oil Red O. Liver fat was stained red. (B) Quantification of liver fat contents. Frozen livers were used for measuring the concentrations of hepatic triglycerides, free fatty acids, and total cholesterol with various commercially available kits. \* $P < 0.05$ .  $n = 5$ .

level in the uterus (Ansell et al., 2004, 2005). Xie et al. revealed a feedback mechanism between Nrf2 and estrogen in liver ischemia and reperfusion (I/R) Guo et al., 2015. I/R-induced Nrf2 activation directly upregulates estrogen sulfotransferase and in turn increases estrogen breakdown, limiting Nrf2 activity and gender-dependently affecting I/R injury (Guo et al., 2015). In addition, the crosstalk of Nrf2 signaling with the PTEN-GSK-3- $\beta$ -TrCP pathway and the p62-mediated autophagy pathway has been demonstrated (Komatsu et al., 2010; Ni et al., 2014; Rojo et al., 2014; Taguchi et al., 2014). Han et al. (2014) uncovered an ER $\alpha$ /liver X receptor (LXR)/sterol regulatory element-binding protein (SREBP) 1 pathway modulating hepatic lipid metabolism (Han et al., 2014). They demonstrate that ER $\alpha$  interacts with LXR and inhibits LXR-dependent transcription of *SREBP1*, a critical fatty acid biosynthesis regulator, contributing to estrogen's liver fat-lowering effect. In our studies, we found that estrogen treatment did not significantly alter hepatic *SREBP1* expression compared with *Nrf2*<sup>+/+</sup> and *Nrf2*<sup>-/-</sup> HFD-fed mice (Supplemental Table 1). This finding suggests that Nrf2-dependent enhancement of the liver fat-lowering effect of estrogen may not be via this ER $\alpha$ /LXR/SREBP1 pathway. Here, we created a novel connection between the Nrf2- and ER $\alpha$ -mediated signaling pathway in lipid metabolism. We believe that our finding will provide a critical mechanistic aspect in understanding liver health and disease, because these two molecules are all essential for maintaining liver homeostasis. Moreover, we demonstrate a potential therapeutic strategy of dual targets (inhibiting Nrf2 and activating ER $\alpha$ ) for NAFLD, which has emerged as the most common chronic liver disorder without a clinical cure in developed countries (Sanyal, 2015).

Our studies revealed the positive correlation of TFF3 with the liver fat-lowering effect of estrogen. We observed that the amplification of the liver fat-lowering effect of E2 in *Nrf2*-null mice with NAFLD was accompanied by further increased hepatic TFF3 induction. TFF family members including TFF1, TFF2, and TFF3 are secretory peptides without a known receptor (Busch and Dünker, 2015). Information regarding their expression, regulation, and function is expanding. TFF3 is expressed along the gastrointestinal tract, promotes wound healing of the gastrointestinal epithelium, and is associated with gastroadenocarcinoma progression (Xiao et al., 2015). It is also expressed in pancreatic  $\beta$  cells and oxytocin-secreting neurons in the hypothalamus, related to cell growth and learning and memory (Jagla et al., 2000; Fueger et al., 2008; Shi et al., 2012). This peptide is induced in biliary duct epithelial cells in biliary diseases (Srivatsa et al., 2002; Nozaki et al., 2004; Sasaki et al., 2007; Jiang et al., 2010). The *TFF3* gene maps to the Obq4 obesity quantitative trait locus, which is highly associated with total calorie intake; indeed, the expression of Obq4 in the intestine is regulated by food intake (Kumar and Smith Richards, 2008; Ge et al., 2015). Hepatic *TFF3* expression is increased in hepatic steatosis and decreased in db/db mice and mice with diet-induced obesity (DIO), suggesting its involvement in lipid metabolism (Guillén et al., 2009; Xue et al., 2013). Adenovirus-mediated 5.5-fold overexpression of mouse TFF3 in the liver reduces blood glucose and improves glucose tolerance in db/db mice and ameliorates insulin resistance in DIO mice (Xue et al., 2013). Adeno-associated virus-mediated overexpression of human TFF3, reaching 900 ng/ml in 2 weeks after virus infection, improves glucose tolerance in



**Fig. 4.** (A) mRNA expression of hepatic Nrf2, NQO-1, ERα, and TFF3. Total RNA was extracted from each liver collected from the experiment illustrated in Fig. 1. Hepatic mRNA expression of the genes indicated was quantified with quantitative real-time PCR. The hepatic mRNA level of each gene in normal chow-fed *Nrf2*<sup>+/+</sup> mice was set to 1. \**P* < 0.05, compared with normal chow-fed *Nrf2*<sup>+/+</sup> mice; #*P* < 0.05, compared with normal chow-fed *Nrf2*<sup>-/-</sup> mice; †*P* < 0.05, compared between *Nrf2*<sup>+/+</sup> and *Nrf2*<sup>-/-</sup> mice. *n* = 5. (B) Protein expression of hepatic NQO-1, ERα, and FABP5. Total liver lysates were prepared from the livers collected from the experiment described in Fig. 1. Western blotting was performed with the antibodies against the proteins indicated. The lanes represent samples prepared from individual mice. (C) Hepatic expression and distribution of TFF3 protein. Formalin-fixed and paraffin-embedded liver sections prepared from the experiment indicated in Fig. 1 were subjected to immunostaining with a TFF3 antibody. TFF3 protein was stained dark brown.



**Fig. 5.** Nrf2- and estrogen-dependent induction of FABP5 in the liver. (A) Hepatic expression of FABP5 mRNA. Total RNA samples prepared from the experiment described in Fig. 4 were used for evaluating the transcript levels of hepatic FABP5 with quantitative real-time PCR. Hepatic mRNA expression of the gene in normal chow-fed *Nrf2*<sup>+/+</sup> mice was set to 1. \**P* < 0.05, compared with normal chow-fed *Nrf2*<sup>+/+</sup> mice; #*P* < 0.05, compared with normal chow-fed *Nrf2*<sup>-/-</sup> mice; †*P* < 0.05, compared between *Nrf2*<sup>+/+</sup> and *Nrf2*<sup>-/-</sup> mice. *n* = 5. (B) Hepatic expression and distribution of FABP5 protein. Formalin-fixed and paraffin-embedded liver sections prepared from the experiment indicated in Fig. 1 were subjected to immunostaining with a FABP5 antibody. FABP5-expressing cells were stained dark brown.

DIO mice without affecting body weight, fasting insulin, and levels of triglycerides, cholesterol, and leptin in the blood (Ge et al., 2015). These two studies highlighted the critical role of TFF3 in maintaining glucose homeostasis. However, it is not clear whether TFF3 overexpression affects hepatic lipid contents and whether human TFF3 is equipotent to mouse TFF3 in mice. Thus, whether TFF3 regulates hepatic lipid metabolism and mediates the liver fat-lowering effect of estrogen warrants further investigation.

Our studies also showed the association of FABP5 with the liver fat-lowering effect of estrogen. In mice with NAFLD, compared with the vehicle control, exogenous E2 increased hepatic FABP5 expression in wild-type mice and further increased its expression in *Nrf2*-null mice. It is evident that the level of FABP5 expression is positively correlated with the liver fat-lowering effect of estrogen. FABP5 belongs to a family of intracellular fatty acid binding proteins with tissue-specific distribution and functions. They bind unesterified long-chain fatty acids and regulate lipid metabolism (fatty acid transport, metabolism, and storage), inflammation, and energy homeostasis (Thumser et al., 2014; Hotamisligil and Bernlohr, 2015). FABP5 has been shown to interact with nuclear receptor

peroxisome proliferator-activated receptor, exhibiting properties of anti-inflammation and antioxidative stress (Berger et al., 2012; Gally et al., 2013). Overexpression of FABP5 in adipose tissue results in increased lipolysis, decreased fat mass, and potentiated insulin resistance (Hertzel et al., 2006). In the liver, FABP5 displays an anti-inflammatory action by regulating macrophage phenotypes (Moore et al., 2015). Consistent with a report showing that FABP5 is negatively regulated by Nrf2 in normal and fatty livers (Chartoumpekis et al., 2013), we additionally revealed that hepatic FABP5 positively responds to estrogen signaling in NAFLD. Notably, we found that FABP5 is the only one exhibiting both Nrf2- and E2-dependant alterations among the examined 84 genes that are associated with fat metabolism and insulin signaling. Taken together, these findings suggest an Nrf2/ER $\alpha$ /FABP5 regulatory pathway that controls hepatic lipid homeostasis. Hence, the function of FABP5 in liver lipid metabolism needs further investigation.

#### Authorship Contributions

*Participated in research design:* Rui, Zou, Zhang, Yang, Dai.

*Conducted experiments:* Rui, Zou, Lee, Nambiar, Lin.

*Performed data analysis:* Rui, Zou, Lee, Lin, Dai.

*Wrote or contributed to the writing of the manuscript:* Rui, Zou, Dai.

#### References

- Ansell PJ, Espinosa-Nicholas C, Curran EM, Judy BM, Philips BJ, Hannink M, and Lubahn DB (2004) In vitro and in vivo regulation of antioxidant response element-dependent gene expression by estrogens. *Endocrinology* **145**:311–317.
- Ansell PJ, Lo SC, Newton LG, Espinosa-Nicholas C, Zhang DD, Liu JH, Hannink M, and Lubahn DB (2005) Repression of cancer protective genes by 17 $\beta$ -estradiol: ligand-dependent interaction between human Nrf2 and estrogen receptor  $\alpha$ . *Mol Cell Endocrinol* **243**:27–34.
- Barros RP and Gustafsson JA (2011) Estrogen receptors and the metabolic network. *Cell Metab* **14**:289–299.
- Berger WT, Ralph BP, Kaczocha M, Sun J, Balius TE, Rizzo RC, Haj-Dahmane S, Ojima I, and Deutsch DG (2012) Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. *PLoS One* **7**:e50968.
- Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, and Aiello RJ (1996) Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. *Proc Natl Acad Sci USA* **93**:10022–10027.
- Bryzgalova G, Lundholm L, Portwood N, Gustafsson JA, Khan A, Efendic S, and Dahlman-Wright K (2008) Mechanisms of antidiabetic and body weight-lowering effects of estrogen in high-fat diet-fed mice. *Am J Physiol Endocrinol Metab* **295**:E904–E912.
- Busch M and Dünker N (2015) Trefoil factor family peptides—friends or foes? *Biomol Concepts* **6**:343–359.
- Chambel SS, Santos-Gonçalves A, and Duarte TL (2015) The dual role of Nrf2 in nonalcoholic fatty liver disease: regulation of antioxidant defenses and hepatic lipid metabolism. *BioMed Res Int* **2015**:597134.
- Chan K, Han XD, and Kan YW (2001) An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. *Proc Natl Acad Sci USA* **98**:4611–4616.
- Chan K, Lu R, Chang JC, and Kan YW (1996) NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. *Proc Natl Acad Sci USA* **93**:13943–13948.
- Chartoumpekis DV, Ziros PG, Zaravinos A, Iskrenova RP, Psyrogiannis AI, Kyriazopoulou VE, Sykiotis GP, and Habeos IG (2013) Hepatic gene expression profiling in Nrf2 knockout mice after long-term high-fat diet-induced obesity. *Oxid Med Cell Longev* **2013**:340731.
- Demir M, Lang S, and Steffen HM (2015) Nonalcoholic fatty liver disease - current status and future directions. *J Dig Dis* **16**:541–557.
- Diep CH, Daniel AR, Mauro LJ, Knutson TP, and Lange CA (2015) Progesterone action in breast, uterine, and ovarian cancers. *J Mol Endocrinol* **54**:R31–R53.
- Dodson M, Redmann M, Rajasekaran NS, Darley-Usmar V, and Zhang J (2015) KEAP1-NRF2 signalling and autophagy in protection against oxidative and reductive proteotoxicity. *Biochem J* **469**:347–355.
- Frank A, Brown LM, and Clegg DJ (2014) The role of hypothalamic estrogen receptors in metabolic regulation. *Front Neuroendocrinol* **35**:550–557.
- Fueger PT, Schisler JC, Lu D, Babu DA, Mirmira RG, Newgard CB, and Hohmeier HE (2008) Trefoil factor 3 stimulates human and rodent pancreatic islet  $\beta$ -cell replication with retention of function. *Mol Endocrinol* **22**:1251–1259.
- Gally F, Kosmider B, Weaver MR, Pate KM, Hartshorn KL, and Oberley-Deegan RE (2013) FABP5 deficiency enhances susceptibility to H1N1 influenza A virus-induced lung inflammation. *Am J Physiol Lung Cell Mol Physiol* **305**:L64–L72.
- Gao H, Bryzgalova G, Hedman E, Khan A, Efendic S, Gustafsson JA, and Dahlman-Wright K (2006) Long-term administration of estradiol decreases expression of hepatic lipogenic genes and improves insulin sensitivity in ob/ob mice: a possible mechanism is through direct regulation of signal transducer and activator of transcription 3. *Mol Endocrinol* **20**:1287–1299.
- Ge H, Gardner J, Wu X, Rulifson I, Wang J, Xiong Y, Ye J, Belouski E, Cao P, and Tang J, et al. (2015) Trefoil factor 3 (TFF3) is regulated by food intake, improves glucose tolerance and induces mucinous metaplasia. *PLoS One* **10**:e0126924.
- Gorrini C, Gang BP, Bassi C, Wakeham A, Baniasadi SP, Hao Z, Li WY, Cescon DW, Li YT, and Molyneux S, et al. (2014) Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway. *Proc Natl Acad Sci USA* **111**:4472–4477.
- Gruvberger S, Ringnér M, Chen Y, Panavally S, Saal LH, Borg A, Fernö M, Peterson C, and Meltzer PS (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. *Cancer Res* **61**:5979–5984.
- Guillén N, Navarro MA, Arnal C, Noone E, Arbonés-Mainar JM, Acín S, Surra JC, Muniesa P, Roche HM, and Osada J (2009) Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver. *Physiol Genomics* **37**:187–198.
- Guo Y, Hu B, Huang H, Tsung A, Gaikwad NW, Xu M, Jiang M, Ren S, Fan J, and Billiar TR, et al. (2015) Estrogen sulfotransferase is an oxidative stress-responsive gene that gender-specifically affects liver ischemia/reperfusion injury. *J Biol Chem* **290**:14754–14764.
- Han SI, Komatsu Y, Murayama A, Steffensen KR, Nakagawa Y, Nakajima Y, Suzuki M, Oie S, Parini P, and Vedin LL, et al. (2014) Estrogen receptor ligands ameliorate fatty liver through a nonclassical estrogen receptor/Liver X receptor pathway in mice. *Hepatology* **59**:1791–1802.
- Hertzel AV, Smith LA, Berg AH, Cline GW, Shulman GI, Scherer PE, and Bernlohr DA (2006) Lipid metabolism and adipokine levels in fatty acid-binding protein null and transgenic mice. *Am J Physiol Endocrinol Metab* **290**:E814–E823.
- Hewitt KN, Pratis K, Jones ME, and Simpson ER (2004) Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. *Endocrinology* **145**:1842–1848.
- Hotamisligil GS and Bernlohr DA (2015) Metabolic functions of FABPs—mechanisms and therapeutic implications. *Nat Rev Endocrinol* **11**:592–605.
- Huang J, Tabbi-Anneni I, Gunda V, and Wang L (2010) Transcription factor Nrf2 regulates SHP and lipogenic gene expression in hepatic lipid metabolism. *Am J Physiol Gastrointest Liver Physiol* **299**:G1211–G1221.
- Huang Y, Li W, Su ZY, and Kong AN (2015) The complexity of the Nrf2 pathway: beyond the antioxidant response. *J Nutr Biochem* **26**:1401–1413.
- Jagla W, Wiede A, Dietzmann K, Rutkowski K, and Hoffmann W (2000) Colocalization of TFF3 peptide and oxytocin in the human hypothalamus. *FASEB J* **14**:1126–1131.
- Jiang GX, Zhong XY, Cui YF, Liu W, Tai S, Wang ZD, Shi YG, Zhao SY, and Li CL (2010) IL-6/STAT3/TFF3 signaling regulates human biliary epithelial cell migration and wound healing in vitro. *Mol Biol Rep* **37**:3813–3818.
- Jones ME, Thorburn AW, Britt KL, Hewitt KN, Wreford NG, Proietto J, Oz OK, Leury BJ, Robertson KM, and Yao S, et al. (2000) Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. *Proc Natl Acad Sci USA* **97**:12735–12740.
- Kim JH, Cho HT, and Kim YJ (2014) The role of estrogen in adipose tissue metabolism: insights into glucose homeostasis regulation. *Endocr J* **61**:1055–1067.
- Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, and Tong KI, et al. (2010) The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. *Nat Cell Biol* **12**:213–223.
- Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, and Gustafsson JA (1997) Comparison of the ligand binding specificity and transcription tissue distribution of estrogen receptors  $\alpha$  and  $\beta$ . *Endocrinology* **138**:863–870.
- Kumar KG and Smith Richards BK (2008) Transcriptional profiling of chromosome 17 quantitative trait loci for carbohydrate and total calorie intake in a mouse congenic strain reveals candidate genes and pathways. *J Nutrigenet Nutrigenomics* **1**:155–171.
- Liao H, Zhou Q, Zhang Z, Wang Q, Sun Y, Yi X, and Feng Y (2012) NRF2 is overexpressed in ovarian epithelial carcinoma and is regulated by gonadotrophin and sex-steroid hormones. *Oncol Rep* **27**:1918–1924.
- Lundholm L, Bryzgalova G, Gao H, Portwood N, Fält S, Berndt KD, Dicker A, Galuska D, Zierath JR, and Gustafsson JA, et al. (2008) The estrogen receptor  $\alpha$ -selective agonist propyl pyrazole triol improves glucose tolerance in ob/ob mice; potential molecular mechanisms. *J Endocrinol* **199**:275–286.
- Mauvais-Jarvis F, Clegg DJ, and Hevener AL (2013) The role of estrogens in control of energy balance and glucose homeostasis. *Endocr Rev* **34**:309–338.
- May FE and Westley BR (1997) Expression of human intestinal trefoil factor in malignant cells and its regulation by oestrogen in breast cancer cells. *J Pathol* **182**:404–413.
- Meng X, Wang M, Wang X, Sun G, Ye J, Xu H, and Sun X (2014) Suppression of NADPH oxidase- and mitochondrion-derived superoxide by Nootginsenoside R1 protects against cerebral ischemia-reperfusion injury through estrogen receptor-dependent activation of Akt/Nrf2 pathways. *Free Radic Res* **48**:823–838.
- Moore SM, Holt VV, Malpass LR, Hines IN, and Wheeler MD (2015) Fatty acid-binding protein 5 limits the anti-inflammatory response in murine macrophages. *Mol Immunol* **67** (Pt B):265–275.
- Ni HM, Woolbright BL, Williams J, Copple B, Cui W, Luyendyk JP, Jaeschke H, and Ding WX (2014) Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. *J Hepatol* **61**:617–625.
- Nozaki I, Lunz JG, 3rd, Specht S, Park JI, Giraud AS, Murase N, and Demetris AJ (2004) Regulation and function of trefoil factor family 3 expression in the biliary tree. *Am J Pathol* **165**:1907–1920.
- Palmer BF and Clegg DJ (2015) The sexual dimorphism of obesity. *Mol Cell Endocrinol* **402**:113–119.
- Pedram A, Razandi M, O'Mahony F, Harvey H, Harvey BJ, and Levin ER (2013) Estrogen reduces lipid content in the liver exclusively from membrane receptor signaling. *Sci Signal* **6**:ra36.

- Roepke TA (2009) Oestrogen modulates hypothalamic control of energy homeostasis through multiple mechanisms. *J Neuroendocrinol* **21**:141–150.
- Rojo AI, Rada P, Mendiola M, Ortega-Molina A, Wojdyla K, Rogowska-Wrzesinska A, Hardisson D, Serrano M, and Cuadrado A (2014) The PTEN/NRF2 axis promotes human carcinogenesis. *Antioxid Redox Signal* **21**:2498–2514.
- Sanyal AJ (2015) Novel therapeutic targets for steatohepatitis. *Clin Res Hepatol Gastroenterol* **39** (Suppl 1):S46–S50.
- Sasaki M, Ikeda H, and Nakanuma Y (2007) Expression profiles of MUC mucins and trefoil factor family (TFF) peptides in the intrahepatic biliary system: physiological distribution and pathological significance. *Prog Histochem Cytochem* **42**:61–110.
- Shen M and Shi H (2015) Sex hormones and their receptors regulate liver energy homeostasis. *Int J Endocrinol* **2015**:294278.
- Shi HS, Yin X, Song L, Guo QJ, and Luo XH (2012) Neuropeptide trefoil factor 3 improves learning and retention of novel object recognition memory in mice. *Behav Brain Res* **227**:265–269.
- Srivatsa G, Giraud AS, Ulaganathan M, Yeomans ND, Dow C, and Nicoll AJ (2002) Biliary epithelial trefoil peptide expression is increased in biliary diseases. *Histopathology* **40**:261–268.
- Suzuki T and Yamamoto M (2015) Molecular basis of the Keap1-Nrf2 system. *Free Radic Biol Med* **88** (Pt B):93–100.
- Taguchi K, Hirano I, Itoh T, Tanaka M, Miyajima A, Suzuki A, Motohashi H, and Yamamoto M (2014) Nrf2 enhances cholangiocyte expansion in Pten-deficient livers. *Mol Cell Biol* **34**:900–913.
- Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT, and Hayes JD (2015) Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. *Free Radic Biol Med* **88** (Pt B):108–146.
- Thumser AE, Moore JB, and Plant NJ (2014) Fatty acid binding proteins: tissue-specific functions in health and disease. *Curr Opin Clin Nutr Metab Care* **17**:124–129.
- Walter LM, Rogers PA, and Girling JE (2005) The role of progesterone in endometrial angiogenesis in pregnant and ovariectomised mice. *Reproduction* **129**:765–777.
- Wu J, Williams D, Walter GA, Thompson WE, and Sidell N (2014) Estrogen increases Nrf2 activity through activation of the PI3K pathway in MCF-7 breast cancer cells. *Exp Cell Res* **328**:351–360.
- Xiao P, Ling H, Lan G, Liu J, Hu H, and Yang R (2015) Trefoil factors: gastrointestinal-specific proteins associated with gastric cancer. *Clin Chim Acta* **450**:127–134.
- Xu Y, Nedungadi TP, Zhu L, Sobhani N, Irani BG, Davis KE, Zhang X, Zou F, Gent LM, and Hahner LD, et al. (2011) Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction. *Cell Metab* **14**:453–465.
- Xue Y, Shen L, Cui Y, Zhang H, Chen Q, Cui A, Fang F, and Chang Y (2013) Tff3, as a novel peptide, regulates hepatic glucose metabolism. *PLoS One* **8**:e75240.
- Yu J, Zhao Y, Li B, Sun L, and Huo H (2012) 17 $\beta$ -estradiol regulates the expression of antioxidant enzymes in myocardial cells by increasing Nrf2 translocation. *J Biochem Mol Toxicol* **26**:264–269.
- Zhang H, Liu Y, Wang L, Li Z, Zhang H, Wu J, Rahman N, Guo Y, Li D, and Li N, et al. (2013a) Differential effects of estrogen/androgen on the prevention of non-alcoholic fatty liver disease in the male rat. *J Lipid Res* **54**:345–357.
- Zhang T, Liang X, Shi L, Wang L, Chen J, Kang C, Zhu J, and Mi M (2013b) Estrogen receptor and PI3K/Akt signaling pathway involvement in S(-)-equol-induced activation of Nrf2/ARE in endothelial cells. *PLoS One* **8**:e79075.
- Zou Y, Lee J, Nambiar SM, Hu M, Rui W, Bao Q, Chan JY, and Dai G (2014) Nrf2 is involved in maintaining hepatocyte identity during liver regeneration. *PLoS One* **9**:e107423.

---

**Address correspondence to:** Dr. Guoli Dai, Department of Biology, Center for Developmental and Regenerative Biology, School of Science, Indiana University–Purdue University Indianapolis, 723 W. Michigan Street, Biology SL332, Indianapolis, IN 46202. E-mail: gdai@iupui.edu or Dr. Yan Yang, Department of Pharmacology, Anhui Medical University, Hefei, China. E-mail: yangyan@ahmu.edu.cn

---